text stringlengths 1 711 |
|---|
$4,570 |
$1,022 $1,111 |
20.9% |
24.3% |
19.0% |
20.0% |
21.0% |
22.0% |
23.0% |
24.0% |
25.0% |
$0 |
$1,000 |
$2,000 |
$3,000 |
$4,000 |
$5,000 |
$6,000 |
2019 2022 |
Sales Segment OI Segment OI Margin |
Source: Company reports. |
Figure 26: Essential Health Profit/Margin Improvement Despite Lower |
Sales |
-6.7% |
8.7% |
+340 bps |
-8% |
-6% |
-4% |
-2% |
0% |
2% |
4% |
6% |
8% |
10% |
Sales 2022 vs. 2019 Segment OI 2022 vs. 2019 Segment OI Margin 2022 vs. 2019 |
Source: Company reports. |
We expect the company to continually evaluate opportunities to streamline its portfolio |
by eliminating tail SKUs (likely an annual exercise as it is with any CPG company), |
although from our perspective it appears that much of the heavy lifting of portfolio |
optimization is largely behind the company at this point. Looking ahead, M&A figures |
to continue to play a role in shaping of the portfolio, likely continuing in the higher |
growth/margin segments within Consumer Health (e.g., Self Care and Skin Health & |
Beauty), and we expect M&A to be more bolt-on in nature vs. transformational |
transactions. With strong FCF generation and a healthy balance sheet (post-IPO net |
debt-to-TTM EBITDA likely ~2.1x) KVUE should have ample dry powder to deploy to |
M&A if it deems fit, and we think management is likely earmarking $500-750M for |
acquisitions in the years ahead (vs. JPMe FCF $2.4B/$2.5B/$2.8B in 2023/2024/2025), |
although we note that we dont account for any M&A benefit within our P&L estimates. |
Supply Chain Optimization to Reduce Complexity, Increase Efficiency and |
Resiliency |
While supply chain challenges plagued KVUE during 2022 given input shortages and |
transportation challenges, the company has undertaken efforts since 2019 to structurally |
improve its supply chain by investing in digitization to increase efficiency and resiliency |
and by reduced complexity through external manufacturer rationalization. |
Pre-pandemic, KVUEs supply chain focus was mostly on operational excellence, |
quality control, and margin maximization, but COVID tested the resilience and |
flexibility of the supply chain and uncovered a lack of redundancy that impacted |
product availability and service. The company noted that in 2021/2022 64%/63% of its |
scheduled capital spend for supply chain investments was allocated to digitization |
(automation), which ultimately allows for better demand planning, capacity, and |
resilience. Some examples include 1) shift to conditions-based maintenance from |
scheduled maintenance given better monitoring capabilities allows for better capacity |
availability while also alleviating labor challenges; 2) complexity reduction through |
SKU rationalization and product design standardization (e.g., bottle types) and reducing |
the number of small external manufacturers (e.g., company eliminated 60% of small |
external manufacturers); 3) increasing dual sourcing and reducing specification on |
critical ingredients to improve availability/resilience; and 4) integrated business |
planning to optimize forecasting and inventory management, leading to better |
profitability and cash flow. |
This document is being provided for the exclusive use of DAVID WANG at MARLOWE PARTNERS LP. |
20 |
Andrea Teixeira, CFA AC |
(1-212) 622-6735 |
andrea.f.teixeira@jpmorgan.com |
North America Equity Research |
29 May 2023 J PMORGAN |
All in, the companys in-house manufacturing footprint of 25 facilities accounted for |
56% of production volume in 2022 while the remaining 44% of production was handled |
by seven JNJ facilities under transition manufacturing agreements and 230 external manufacturers (as noted above, a 60% reduction since 2019). Within the segments, Skin |
Health & Beauty tends to be more out-sourced while Self Care is more in house. The company also operates 114 distribution centers and 38 customer service centers globally, |
with distribution often operated in partnership with third parties. |
Digital Marketing Improving ROI as Company Shifts to Omnichannel About 6% of KVUEs sales are through pure-play e-commerce, but mix more than |
doubles to 13% including retailer.com (largely in line with CPG peers), and the companys online sales have grown at a +20% CAGR from 2020 to 2022. One of the drivers beyond the general shift of consumption to online channels is the companys |
focus on digital marketing, which has taken shape over the past several years. In North |
America, for example, the digital marketing spend accounted for 73% of total marketing |
spend in 2022, which was up from 59% in 2020 and 49% in 2019 and drove a +29% |
increase in media ROI as of October 2022 and collective 13 points increase in U.S. |
household penetration from 2019 to 2021. The company has pointed to digital investments driving improved social media engagement including for Neutrogena a 660% increase in followers from August to December 2021 as a result of its SkinU |
campaign on TikTok, which generated over 300 million social media impressions. The company has also focused a lot of its digital efforts outside of the U.S., in particularly in |
APAC, which accounted for 63% of global e-commerce sales in 2020. Investments |
behind digital media are largely table stakes for CPG companies at this stage as a cost- |
efficient and effective way to engage with consumers. Digital focus is likely to continue to be important, especially for segments or brands appealing to younger digitally-native consumers like within Skin Health & Beauty. The company does continue to invest in |
traditional media, although it largely depends on where the consumer is in that particular |
market. |
Opportunity for Margin Expansion as KVUE Exits TSA/TMA |
Looking ahead, one of the bigger areas for margin expansion opportunity for KVUE will likely be in exiting transition services agreements (TSA) and transition |
manufacturing agreements (TMA) with JNJ post-separation, which run on a cost-plus |
model. Of the roughly $100M in incremental costs associated with being a stand-alone company, we estimate that the TSA and TMA could be roughly 50-60% of the incremental costs (i.e., 30-40 bps margin opportunity of roughly 130 bps EBITDA margin expansion modeled for 2022-2025). |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.